{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:10:50Z","timestamp":1790691050153,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.farma.2026.07.012","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:54:19Z","timestamp":1790690059000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibidores de los puntos de control inmune frente a quimioterapia en la COVID-19 en pacientes con c\u00e1ncer"],"prefix":"10.1016","author":[{"given":"Maria Susana","family":"Fortes Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Herrero Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vazquez Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Garcia Beloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Sanjuan Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cerdeira Regueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Castro Luaces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Fernandez Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Perez Landeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Martinez-Lopez de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.farma.2026.07.012_bb0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumoniae in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2026.07.012_bb0010","unstructured":"World Health Organization (WHO). WHO Health Emergencies Programme. WHO COVID-19 Dashboard. Actualizada el 14 de junio de 2026. [consultado 06 Mar 2026]. Disponible en: https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c."},{"key":"10.1016\/j.farma.2026.07.012_bb0015","unstructured":"Centro de Coordinaci\u00f3n de. Alertas y Emergencias Sanitarias. Actualizaci\u00f3n n\u00b0 672. Enfermedad por el coronavirus (COVID-19). Actualizada el 30 de junio de 2023. [consultado. 2026]. Disponible En; Mar:06. https:\/\/www.sanidad.gob.es\/areas\/alertasEmergenciasSanitarias\/alertasActuales\/nCov\/documentos\/Actualizacion_672_COVID-19.pdf"},{"issue":"7","key":"10.1016\/j.farma.2026.07.012_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.medcli.2024.04.009","article-title":"Carga de la COVID-19 variante \u00f3micron en pacientes inmunocomprometidos en Espa\u00f1a: revisi\u00f3n sistem\u00e1tica","volume":"163","author":"Ortiz-de-Lejarazu","year":"2024","journal-title":"Med Clin"},{"issue":"15","key":"10.1016\/j.farma.2026.07.012_bb0025","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/imt-2021-0007","article-title":"Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis","volume":"13","author":"Qian","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.farma.2026.07.012_bb0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12967-021-02798-2","article-title":"Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis","volume":"19","author":"Isgro","year":"2021","journal-title":"J Transl Med"},{"issue":"5","key":"10.1016\/j.farma.2026.07.012_bb0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/cancers17050821","article-title":"Current landscape and future directions in cancer immunotherapy: therapies, trials, and challenges","volume":"17","author":"Bandara","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.farma.2026.07.012_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.farma.2026.07.012_bb0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/2326-6066.CIR-21-0008","article-title":"At the crossroads: COVID-19 and immune-checkpoint blockade for cancer","volume":"9","author":"Garassino","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.farma.2026.07.012_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/CJI.0000000000000440","article-title":"A single center retrospective study of the impact of covid-19 infection on immune-related adverse events in cancer patients receiving immune checkpoint inhibitors","volume":"45","author":"Guo","year":"2022","journal-title":"J Immunother"},{"key":"10.1016\/j.farma.2026.07.012_bb0055","doi-asserted-by":"crossref","first-page":"695242","DOI":"10.3389\/fimmu.2021.695242","article-title":"PD-L1 dysregulation in COVID-19 patients","volume":"12","author":"Sabbatino","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.farma.2026.07.012_bb0060","doi-asserted-by":"crossref","first-page":"e001694","DOI":"10.1136\/jitc-2020-001694","article-title":"SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study","volume":"9","author":"Mandala","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.farma.2026.07.012_bb0065","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.3390\/cancers14235954","article-title":"Clinical outcomes in COVID-19 patients treated with immunotherapy","volume":"14","author":"Hatic","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.farma.2026.07.012_bb0070","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s43018-020-00120-5","article-title":"Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort","volume":"1","author":"Albiges","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.farma.2026.07.012_bb0075","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3389\/fonc.2020.01777","article-title":"Outcomes of COVID-19 in patients with lung cancer treated in a tertiary hospital in Madrid","volume":"10","author":"Calles","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.farma.2026.07.012_bb0080","doi-asserted-by":"crossref","first-page":"1259112","DOI":"10.3389\/fimmu.2024.1259112","article-title":"Association of immune checkpoint inhibitors with SARS-CoV-2 infection rate and prognosis in patients with solid tumors: a systematic review and meta-analysis","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"issue":"Pt A","key":"10.1016\/j.farma.2026.07.012_bb0085","doi-asserted-by":"crossref","first-page":"108242","DOI":"10.1016\/j.intimp.2021.108242","article-title":"Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: the systematic review and meta-analysis","volume":"101","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.farma.2026.07.012_bb0090","unstructured":"International Agency for Research on Cancer (IARC). Global cancer observatory: cancer today. Actualizado el 07 de julio de 2026. [consultado. 2026]. Disponible En; Mar:06. https:\/\/gco.iarc.fr\/en."},{"issue":"6","key":"10.1016\/j.farma.2026.07.012_bb0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1470-2045(19)30163-9","article-title":"Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study","volume":"20","author":"Wilson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.farma.2026.07.012_bb0100","unstructured":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Recomendaciones SEIMC para el manejo cl\u00ednico de pacientes con COVID-19. SEIMC. Actualizado 09 Dic 2020. [consultado 06 Mar 2026]. Disponible en: https:\/\/seimc.org\/wp-content\/uploads\/2025\/06\/seimc-rc-2020-COVID19-manejoclinico-v201209.pdf."},{"issue":"2","key":"10.1016\/j.farma.2026.07.012_bb0105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaoncol.2020.6778","article-title":"Incidence of SARS-CoV-2 infection among patients undergoing active antitumor treatment in Italy","volume":"7","author":"Aschele","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.farma.2026.07.012_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920968463","article-title":"Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.farma.2026.07.012_bb0115","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.3390\/cancers12092352","article-title":"Low incidence of SARS-CoV-2 in patients with solid tumors on active treatment: an observational study at a tertiary cancer centre in Lombardy, Italy","volume":"12","author":"Bertuzzi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.farma.2026.07.012_bb0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejca.2020.11.015","article-title":"SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: a survey of the German ADOREG melanoma registry","volume":"144","author":"Moritz","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.farma.2026.07.012_bb0125","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S2213-2600(20)30170-3","article-title":"Challenges in lung cancer therapy during the COVID-19 pandemic","volume":"8","author":"Calabr\u00f2","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.farma.2026.07.012_bb0130","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s43018-020-00122-3","article-title":"The immuno-oncological challenge of COVID-19","volume":"1","author":"Derosa","year":"2020","journal-title":"Nat Cancer"},{"issue":"7","key":"10.1016\/j.farma.2026.07.012_bb0135","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10241","key":"10.1016\/j.farma.2026.07.012_bb0140","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.farma.2026.07.012_bb0145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00262-021-02990-9","article-title":"Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis","volume":"71","author":"Lazarus","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.farma.2026.07.012_bb0150","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:54:24Z","timestamp":1790690064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S1130634326001819"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.07.012","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibidores de los puntos de control inmune frente a quimioterapia en la COVID-19 en pacientes con c\u00e1ncer","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}